Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
نویسندگان
چکیده
منابع مشابه
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.
Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles. Two patients achieved a partial response (10%), and 17 patients (81%) had stable disease. The median progression-f...
متن کاملFailures of 1 week on, 1 week off antiretroviral therapies in a randomized trial.
BACKGROUND Scheduled treatment interruptions are being evaluated in an effort to decrease costs and side effects of highly active antiretroviral therapy (HAART). A schedule of 1 week on and 1 week off therapy offers the promise of 50% less drug exposure with continuously undetectable HIV RNA concentration. METHODS In the Staccato study 600 patients on successful HAART were to be randomized to...
متن کاملBevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
BACKGROUND Angiogenesis inhibition is a rational treatment strategy for high-grade glioma (HGG). Combined antiangiogenic therapy and chemotherapy could be beneficial, taking advantage of different mechanisms of antitumour activity of both therapies. We carried out a phase I-II clinical trial with the combination of bevacizumab and continuous dose-intense temozolomide (TMZ) for patients with a r...
متن کاملDose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
BACKGROUND Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150-200 mg/m(2)/day on days 1-5 every 4 weeks. In this study, a new alternative dose-dense regimen of temozolomide was explored in patients with recurrent brain tumors. PATIENTS AND METHODS In this study, we evaluated the safety, dose-limiting toxicity, maximum tolerated dose, rec...
متن کاملPhase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM). However, few options are effective for patients who experience treatment failure. We conducted a multicenter, phase II study to assess the efficacy and safety of continuous dose-intense TMZ for recurrent GBM. PATIENTS AND METHODS Patients with malig...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neuro-Oncology
سال: 2012
ISSN: 0167-594X,1573-7373
DOI: 10.1007/s11060-012-0832-5